知镜 Cognispect · 医学文献与研究工作台

Optimal strategy for treatment of atherosclerotic cardiovascular disease-comparison of clopidogrel-based antiplatelet agent treatment versus aspirin plus low dose rivaroxaban therapy (OACART study): a study protocol for a multicenter, open-label, randomized, non-inferiority trial.

Kwun JS, Yoon CH, Jeon KH, Cho HW, Park JJ, Kang SH, Lee W, Suh JW, Youn TJ, Kang HJ, Min PK, Yu CW, Lee JH, Rha SW, Shin S, Lee BK, Youn YJ, Ko YG, Jang JY, Lee JK, Park KH, Choi YJ, Lee SR, Park SD, Cho DK, Cho YH, Kim JH, Jeong JO, Cho J, Kim SY, Kang TS, Lee SU, Chae IH.
Trials · 2026-07-30 · PMID 42934720

文献摘要

Background Recent studies have demonstrated the superior benefits of clopidogrel compared to aspirin in reducing mortality, myocardial infarction, stroke, and hospitalization in chronic stable patients with coronary stenting. Furthermore, dual pathway inhibition by combining low-dose rivaroxaban with aspirin (DPI) has shown superior effects in preventing cardiovascular death, myocardial infarction, and stroke in stable atherosclerotic patients. However, no studies have directly compared these treatment strategies in the same population. This randomized controlled trial aims to compare clopidogrel-based antiplatelet therapy with or without aspirin (CAPT) to DPI in a 1:1 ratio in patients with high-risk coronary artery disease (CAD) or in patients with both CAD and peripheral artery disease (PAD). Methods Optimal strategy for treatment of Atherosclerotic cardiovascular disease-comparison of Clopidogrel-based Antiplatelet agent treatment versus aspirin plus low dose Rivaroxaban Therapy (OACART) trial is a randomized multi-center study comparing the performance of the maintaining CAPT or DPI in a 1:1 ratio. The trial is powered for the non-inferiority of the CAPT in patients with chronic stable high-risk CAD or CAD+PAD to DPI with respect to the primary and secondary efficacy endpoints at 36 months. Results Between November 2023 and April 2026, we will recruit 2758 participants from multi-center in Korea, and we will examine the net clinical outcome, including all-cause death, any myocardial infarction, any stroke, any ischemia-driven revascularization (CAD or PAD), acute limb ischemia, any major or minor amputations, any acute thromboembolism, and International Society on Thrombosis and Haemostasis major bleeding at 36 months after study enrollment. Conclusions OACART trial will provide the optimal antithrombotic treatment strategy for patients with stable high-risk atherosclerosis. Trial registration Clinical Research Information Service (CRIS) of Republic of Korea, KCT0008458, registered on May 22, 2023. https://cris.nih.go.kr/cris/search/detailSearch.do?seq=28968&search_page=L.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。